Based on this discovery, T cell immune checkpoint receptors are currently major therapeutic targets in cancer, with monoclonal antibodies (mAbs) that block CTLA4 and PD1/PDL1 in the clinic since 2010 (5, 6). This evidence concerns the gene PDCD1 and cancer.